A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.
The palliative efficacy of strontium-89 chloride has been evaluated in a prospective double-blind crossover study comparing it with stable strontium as placebo in 32 patients with prostate cancer metastatic to bone. Response was assessed 5 weeks after each treatment. 26 patients were evaluable. Complete pain relief was only reported following strontium-89 injection. Statistical comparison between placebo and strontium-89 showed clear evidence of a therapeutic response to strontium-89 compared with only a limited placebo effect (P less than 0.01).
Lewington
V J
VJ
Department of Nuclear Medicine, Southampton General Hospital, U.K.
McEwan
A J
AJ
Ackery
D M
DM
Bayly
R J
RJ
Keeling
D H
DH
Macleod
P M
PM
Porter
A T
AT
Zivanovic
M A
MA
D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000517:prevention & control; D010166:Palliative Care; D010976:Platelet Count / Q000528:radiation effects; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000532:radiotherapy; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D013326:Strontium Radioisotopes